SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Repros Therapeutics Inc. Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal® Clinical Program